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Abstract We describe the ﬁrst case of efavirenz-induced
urolithiasis in a 47-year-old HIV-positive patient. Uri-
nary obstruction led to pyelonephritis and septic shock,
requiring emergency ureteral catheterisation. The sub-
sequent clinical course was favourable, allowing the
patient’s discharge on day 5. A 7 mm, radio-translucent,
non-crystalline, beige stone was extracted during cathe-
terisation. Stone analysis by Fourier transform infrared
spectrometry, liquid chromatography and mass spec-
trometry revealed a stone composed of efavirenz (EFV)
metabolites M4, M5, M8 (as described by Mutlib et al.
in 1999) and approximately 50% of unspeciﬁed proteins.
EFV is a non-nucleoside reverse transcriptase inhibitor
introduced to European markets in 1999. It is principally
metabolised by cytochrome P450 3A4 and 2B6. Of the
dose, 14–34% is excreted in the urine, 1% as unchanged
drug. The patient had been taking 600 mg EFV per day
for 3 years. As EFV-induced urolithiasis has not been
reported so far, we would like to draw the attention
of the medical community to this potentially severe
complication.
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Introduction
Efavirenz is a non-nucleoside reverse transcriptase
inhibitor (NNRTI) approved for HIV therapy in the late
1990s. Its synergistic eﬀects with other antiviral agents
and its low cross-resistance have made it an essential
part of modern combination therapies. The main ad-
verse eﬀects include skin rash and nervous system
symptoms [1, 2]. As EFV-induced urolithiasis has not
been reported so far, we would like to draw the attention
of the medical community to this potentially severe
complication.
Case report
A 47-year-old man presented to the emergency depart-
ment with fever, chills and 6 week history of left ﬂank
pain. He had contracted HIV 6 years previously and
been treated successively with several antiretroviral
drugs, including indinavir which had been stopped
3 years previously, due to lipodystrophy. His current
regimen of efavirenz, abacavir and lamivudine proved
eﬀective, with a CD4 count of 543/mm3 [3]. Efavirenz
600 mg once daily had been introduced 3 years before.
Fig. 1 Ultrasonographic image of left hydronephrosis
G. J. Wirth (&) Æ C. E. Iselin
Division of Urology, Department of Surgery,
University Hospital of Geneva, Geneva, Switzerland
E-mail: jgwirth@yahoo.com
J. Teuscher Æ J. D. Graf
Central Laboratory of Clinical Chemistry,
University Hospital of Geneva, Geneva, Switzerland
Urol Res (2006) 34: 288–289
DOI 10.1007/s00240-006-0052-6
Physical examination on admission revealed 38.6C
fever, mild distress and left ﬂank tenderness. Blood
analysis was signiﬁcant for a white blood cell count of
33,000/mm3, C-reactive protein of 180 mg/l and creati-
nine of 128 lmol/l. Urinalysis showed 100 leucocytes,
ﬁve erythrocytes and 3+ bacteria/high power ﬁeld
(HPF). Urine and blood cultures revealed > 105 Esc-
herichia coli. Renal echography demonstrated left hy-
dronephrosis; no obstacle was detected. (Fig. 1). No
calculi were seen on plain abdominal radiography.
Pyelonephritis led to septic shock a few hours after
admission, requiring emergency ureteral catheterisation
and systemic cardiovascular support. A 7 mm, radio-
translucent, non-crystalline, beige stone was extracted
during catheterisation. Per-operative creatinine level of
208 lmol/l progressively regressed to 112 lmol/l 4 days
later. The patient’s subsequent clinical course was
favourable, allowing his discharge on day ﬁve. Six
months later, he is asymptomatic and shows no signs of
recurrence. Efavirenz therapy was pursued with the
same dosage.
Stone analysis by Fourier transform infrared spec-
trometry, liquid chromatography and mass spectrome-
try revealed a stone composed of the four major
efavirenz metabolites and approximately 50% of
unspeciﬁed proteins (Fig. 2).
Discussion
Drug-induced stones represent a highly heterogeneous
entity with diﬀerent aetiologies, changing epidemiology
and speciﬁc clinical characteristics, accounting for 1–2%
of all cases of urolithiasis [3]. HIV-positive patients are
particularly at risk of developing renal stones, as their
treatment frequently includes known lithogenic drugs
such as indinavir and some sulfamides (i.e. sulfadiazine
and sulfamethoxazole). Knowledge of drug lithogenicity
can be of major help in the early treatment and pre-
vention of urolithiasis and obstructive pyelonephritis.
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Fig. 2 Infrared spectrograms of
efavirenz (Stocrin hard
tablets) (black) and a probe of
the calculus (grey). Both curves
show the typical triple bond at
2,250 cm1. Similar absorption
bands were distinguished in
both spectra at 3,319, 2,250,
1,737, 1,317, 1,250, 1,190, 918
and 745 cm1
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